UCSF PANC Cyst Registry (UCSF PCR)
Population-Based Analysis of Neoplastic Changes in Cystic Lesions of the Pancreas.
Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provides an opportunity to diagnose pancreatic malignancy at an early, curable stage yet also increases the potential to over-treat clinically insignificant lesions. This presents a clinical challenge to prevent unnecessary resection of indolent disease, with associated risks of infections, bleeding, diabetes, and costly disability. Unfortunately, there is little information on the epidemiology and natural history of pancreatic cysts to help guide management.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study develops a large, prospectively managed, electronic, patient-directed pancreatic cyst registry based at UCSF. The UCSF Pancreatic Cystic Lesions Registry (PANC Cyst) will facilitate work to improve clinical care and understanding of pancreatic cysts by prospective follow-up of patients with cystic lesions, especially the diagnostically challenging small cysts, to identify factors related to cyst formation and progression to malignancy. Longitudinal data capture that includes clinical outcomes will also enable us to more precisely define anatomic, radiographic and biomarker information that can be used to differentiate populations of patients for whom surgery is indicated, surveillance is warranted, or no further evaluation is necessary.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Charysa Santos, BS
- Phone Number: 415-514-6914
- Email: Charysa.Santos@ucsf.edu
Study Contact Backup
- Name: Kimberly S Kirkwood, MD
- Phone Number: 415-502-5577
- Email: kim.kirkwood@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California, San Francisco
-
Contact:
- Charysa Santos, BS
- Phone Number: 415-514-6914
- Email: Charysa.Santos@ucsf.edu
-
Contact:
- M.D.
- Phone Number: 877-827-3222
- Email: cancertrials@ucsf.edu
-
Principal Investigator:
- Kimberly Kirkwood, MD
-
Principal Investigator:
- Paige M Bracci, PhD, MPH, MS
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The majority of patients in this study will be over the age of 60 years old, due to the natural age distribution of pancreatic cysts. There will be an approximately even distribution of males and females.
Description
Inclusion Criteria:
- The inclusion criteria for this study are intentionally broad. Eligible patients for prospective enrollment will include
- Adults ≥ 30 years of age
- Have a radiographic or endoscopic diagnosis of at least one pancreatic cysts regardless of treatment status,
- No history of pancreatic cancer,
- Can speak and read English,
- Have access to a computer or mobile device (~95% of U.S. population); and
- Are able to complete an electronic informed consent.
Exclusion Criteria:
- Patients who don't speak English,
- Don't have access to a computer or mobile device; or
- Patients who have a cancer diagnosis.
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Retrospective
The registry will be populated with a retrospective cohort of patients previously identified as having pancreatic cysts. |
|
|
Prospective
The prospectively enrolled patients in this study are the primary population of interest. |
There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cancer
Time Frame: 1-10 years
|
While not the primary outcome measure, the development of cancer from a pancreatic cyst is a critically important study endpoint, which the investigators do not expect to be frequent occurrence. |
1-10 years
|
|
Indolency
Time Frame: 1-10 years
|
If a patient with a pancreatic cyst experiences no or minimal change in size, and no development of worrisome or high-risk stigmata (Tanaka 2017), this will be considered to be an indolent lesion. Most patients will fall under this category. |
1-10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kimberly S Kirkwood, MD, University of California, San Francisco
- Principal Investigator: Paige M Bracci, PhD, MPH, MS, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Digestive System Neoplasms
- Digestive System Diseases
- Endocrine Gland Neoplasms
- Neoplasms, Glandular and Epithelial
- Adenoma
- Cysts
- Neoplasms, Cystic, Mucinous, and Serous
- Neoplasms, Ductal, Lobular, and Medullary
- Cystadenoma
- Pancreatic Intraductal Neoplasms
- Pancreatic Neoplasms
- Pancreatic Cyst
- Pancreatic Diseases
- Mucocele
- Cystadenoma, Serous
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Surveys and Questionnaires
Other Study ID Numbers
Other Study ID Numbers
- 214521
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.